Synergistic Effects of Plasma <i>p</i> ‐tau217 and GFAP on Neurodegeneration and Cognitive Decline in Cognitively Unimpaired Individuals

Plasma p-tau217 is associated with longitudinal neurodegeneration and cognitive decline even in CU individuals. The observed interaction with plasma GFAP may suggest an early role of astroglial reactivity in neurodegeneration, particularly in medial temporal lobe regions. These findings underscore the utility of plasma p-tau217 as a diagnostic tool and for stratifying high-risk individuals in preclinical Alzheimer's.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70856_098969
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Synergistic Effects of Plasma p ‐tau217 and GFAP on Neurodegeneration and Cognitive Decline in Cognitively Unimpaired Individuals

Theresa A. Day, Armand González Escalante, Raffaele Cacciaglia, Gemma Salvadó et al.
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
article

Synergistic Effects of Plasma p ‐tau217 and GFAP on Neurodegeneration and Cognitive Decline in Cognitively Unimpaired Individuals

Theresa A. Day, Armand González Escalante, Raffaele Cacciaglia, Gemma Salvadó, Paula Ortiz‐Romero, Kaj Blennow, Gonzalo Sánchez‐Benavides, Oriol Grau‐Rivera, Henrik Zetterberg, Juan Domingo Gispert, Marc Suárez‐Calvet, Jose Luis Molinuevo
article en

Abstract

Plasma p-tau217 is associated with longitudinal neurodegeneration and cognitive decline even in CU individuals. The observed interaction with plasma GFAP may suggest an early role of astroglial reactivity in neurodegeneration, particularly in medial temporal lobe regions. These findings underscore the utility of plasma p-tau217 as a diagnostic tool and for stratifying high-risk individuals in preclinical Alzheimer's.

Alzheimer s & DementiaVol. 21(S2)
Lundbeck (Denmark) (DK), University of Wisconsin–Madison (US), Eli Lilly (United States) (US), Universitat Pompeu Fabra (ES), Lund University (SE), Hong Kong Science and Technology Parks Corporation (HK), Sahlgrenska University Hospital (SE), Instituto de Salud Carlos III (ES), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES), Pasqual Maragall Foundation (ES), UK Dementia Research Institute (GB), Barcelonaβeta Brain Research Center (ES), Hospital Del Mar (ES), Municipal Institute for Medical Research (ES), AstraZeneca (Spain) (ES), Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (ES), National Hospital for Neurology and Neurosurgery (GB), Hospital del Mar Research Institute (ES), University College London (GB), University of Gothenburg (SE)
Openalex Percentile: Top 34%
Dementia and Cognitive Impairment Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.